AEON vs. ATAI, ENTA, XBIT, IMMP, ME, DSGN, ACRV, FHTX, ALDX, and TSVT Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), 23andMe (ME), Design Therapeutics (DSGN), Acrivon Therapeutics (ACRV), Foghorn Therapeutics (FHTX), Aldeyra Therapeutics (ALDX), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical preparations" industry.
Atai Life Sciences (NASDAQ:ATAI ) and AEON Biopharma (NASDAQ:AEON ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.
In the previous week, AEON Biopharma had 1 more articles in the media than Atai Life Sciences. MarketBeat recorded 5 mentions for AEON Biopharma and 4 mentions for Atai Life Sciences. AEON Biopharma's average media sentiment score of 0.67 beat Atai Life Sciences' score of 0.06 indicating that Atai Life Sciences is being referred to more favorably in the media.
Atai Life Sciences received 321 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 65.99% of users gave Atai Life Sciences an outperform vote.
AEON Biopharma has lower revenue, but higher earnings than Atai Life Sciences.
Atai Life Sciences currently has a consensus target price of $10.50, suggesting a potential upside of 568.79%. AEON Biopharma has a consensus target price of $6.00, suggesting a potential upside of 279.75%. Given AEON Biopharma's higher possible upside, equities research analysts plainly believe Atai Life Sciences is more favorable than AEON Biopharma.
28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by company insiders. Comparatively, 20.0% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Atai Life Sciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
AEON Biopharma has a net margin of 0.00% compared to AEON Biopharma's net margin of -12,810.51%. Atai Life Sciences' return on equity of 0.00% beat AEON Biopharma's return on equity.
Summary Atai Life Sciences beats AEON Biopharma on 9 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
AEON Biopharma Competitors List
Related Companies and Tools
